'Steady Bullish' Options Activity in Pfizer (PFE) Ahead of Q4 Earnings Announcement on Jan. 30th -Susquehanna

Intel, healthcare shares boost lift Wall St. to record

January 26, 2018 7:44 AM EST

By Chuck Mikolajczak

NEW YORK (Reuters) - The latest round of strong earnings reports, including from Intel and AbbVie, along with continued weakness in the dollar lifted each of the major Wall Street indexes to closing records on Friday.

The three main indexes notched their best four-week run since 2016.

Intel's (NASDAQ: INTC) shares surged as high as $50.15, their highest level since October 2000, and closed up 10.55 percent at $50.08 after results indicated that the chipmaker's shift to higher-margin data-center business was working.

AbbVie's (NYSE: ABBV) shares jumped... More

Johnson & Johnson (JNJ) Does Not Plan Bid for Pfizer's (PFE) Consumer Health Unit - Reuters

January 25, 2018 9:36 AM EST

Johnson & Johnson (NYSE: JNJ) said it does not intend to make an offer for Pfizer's (NYSE: PFE) consumer health unit - Reuters.

GlaxoSmithKline (NYSE: GSK), Reckitt Benckiser among bidders lining up for tentative offers for the unit. Deadline for initial bids is Feb 1. Pfizer is seeking $20 billion for the unit.

... More

Exclusive: J&J out of race for Pfizer's $20 billion consumer unit as deadline looms

January 25, 2018 9:34 AM EST

By Pamela Barbaglia, Bill Berkrot and Arno Schuetze

LONDON/NEW YORK/FRANKFURT (Reuters) - Johnson & Johnson (NYSE: JNJ) has pulled out of the race to buy Pfizer's (NYSE: PFE) consumer health business, leaving GlaxoSmithKline (NYSE: GSK) and Reckitt Benckiser (NYSE: RB) among those preparing bids, according to sources familiar with the matter.

Bidders have until Feb. 1 to submit their non-binding offers for the unit, which makes Advil painkiller, Centrum multivitamins and Chapstick lip... More

Pfizer (PFE) Reports Positive Top-Line Results For Potential Biosimilar To Rituxan/MabThera

January 24, 2018 8:35 AM EST

Pfizer Inc. (NYSE: PFE) today announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-05280586 is being developed by Pfizer as a potential biosimilar to Rituxan® (rituximab-US)/MabThera®1.

The trial demonstrated equivalence in overall response rate (ORR) for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma.

We are pleased to report on our fifth proposed biosimilar monoclonal antibody (mAb) with positive study results. These results reinforce... More